Improved glycaemic control in over 11,000 elderly patients from the IMPROVE™ Study of biphasic insulin aspart 30/70 (BIAsp 30) in eight countries

被引：0

作者：

Borzi, V. ^{[1
]}

Shah, S. ^{[2
]}

Knudsen, V. K. ^{[3
]}

机构：

[1] Vittorio Emanuele Hosp, Dept Internal Med, Catania, Italy

[2] SL Raheja Hosp, Bombay, Maharashtra, India

[3] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark

来源：

DIABETOLOGIA | 2009年 / 52卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

888

引用

页码：S348 / S348

页数：1

共 50 条

[1] Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
Gumprecht, J.
Benroubi, M.
Borzi, V.
Kawamori, R.
Shaban, J.
Shah, S.
Shestakova, M.
Wenying, Y.
Ligthelm, R.
Valensi, P.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (06) : 966 - 972
[2] The pharmacokinetic and pharmacodynamic properties of biphasic insulin aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin aspart 30 (BIAsp 30)
Bott, S
Tusek, C
Heinemann, L
Friberg, HH
Heise, T
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (09) : 545 - 550
[3] Biphasic Insulin Aspart 30/70 (BIAsp 30) Is Well Tolerated Effective in Patients ≥75 Years Old in the IMPROVE™ Study
Borzi, Vito
Rosenberg, Kristine Horn
Benroubi, Marian
DIABETES, 2010, 59 : A554 - A555
[4] Biphasic Insulin Aspart 30 (BIAsp 30) is Safe and Improves Glycaemic Control in Insulin Naive Patients with Type 2 Diabetes
Esteghamati, Alireza
Nakhjavani, Manouchehr
Aminorroaya, Ashraf
Aboutorabi, Robabeh
Niafar, Mitra
Mohammadi, Mohammad
Parvaresh, Ehsan
JOURNAL OF DIABETES & METABOLISM, 2011, 2 (03)
[5] Better glycaemic control for 30,171 insulin-naive patients with type 2 diabetes after starting biphasic insulin aspart 30/70 (BIAsp 30) therapy:: IMPROVE™ study subgroup analysis
Kawamori, R.
Srishyla, M. V.
Wenying, Y.
DIABETOLOGIA, 2008, 51 : S393 - S394
[6] Improved Safety and Efficacy Profile in Patients with Type 2 Diabetes Treated with Biphasic Insulin Aspart 30 (BIAsp 30): Iran Subgroup of the IMPROVE Study
Esteghamati, Alireza
Rajabian, Reza
Amini, Masoud
Bahrami, Amir
Khamseh, Mohammad Ebrahim
Ardekani, Mohammad Afkhami
Rizi, Ehsan Parvaresh
DIABETES, 2009, 58 : A527 - A527
[7] Examining patient outcomes following different regimens of biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) in the large, multinational, IMPROVE™ observational study
Ligthelm, R. J.
Valensi, P.
van der Lubbe, W.
DIABETOLOGIA, 2009, 52 : S94 - S94
[8] Biphasic Insulin Aspart 30 (BIAsp 30) Improves Glycemic Control in Patients with Type 2 Diabetes Regardless of Previous Treatment Regimens: The IMPROVE Study in Iran
Esteghamati, Alireza
Rajabian, Reza
Amini, Masoud
Bahrami, Amir
Khamseh, Mohammad Ebrahim
Ardekani, Mohammad
Rizi, Ehsan Parvaresh
DIABETES, 2009, 58 : A516 - A516
[9] Effect of biphasic insulin aspart 30/70 (BIAsp30) in combination with metformin on glycaemic control in subjects with type 2 diabetes not optimally controlled on oral antidiabetic agents
Naiker, P.
Makan, H. A.
Omar, M. A. K.
Kedijang, T.
Kong, L. L. L.
DIABETOLOGIA, 2006, 49 : 599 - 600
[10] Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) from the PREFER treat-to-target study
Liebl, Andreas
Prager, Rudolf
Kaiser, Marcel
Binz, Katharina
Gallwitz, Baptist
DIABETES, 2006, 55 : A460 - A461

← 1 2 3 4 5 →